Nidovirales Infections clinical trials

The registry lists 21 studies for Nidovirales Infections across more than 10 countries. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-10-15. Counting its 5 narrower conditions too, such as COVID-19: 8,803 studies, 639 open.

Get an email when these change. Save the Nidovirales Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 15
Recruiting: 3
Terminated: 2
Withdrawn: 1

Phase

Phase 3: 15
Phase 2: 5
Phase 4: 2
Phase 1: 1

Where

United States: 19
Denmark: 8
Spain: 8
Singapore: 7
Uganda: 6
Switzerland: 6

Who runs them

National Institute of Allergy and Infectious Diseases (NIAID) (12) · Pfizer (2) · BioNTech SE (2) · Assistance Publique - Hôpitaux de Paris (2) · Adrian Hernandez (1) · Washington University School of Medicine (1) · Celularity Incorporated (1)

What is being tested here

Drugs under test in Nidovirales Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
BNT162 Vaccine	2	1	2
Ibuzatrelvir	1	1	1
Bamlanivimab	0	3	3
Remdesivir	0	2	2
Aviptadil	0	2	2
Amubarvimab	0	2	2
Romlusevimab	0	2	2
Ensovibep	0	2	2
Sotrovimab	0	2	2
Lufotrelvir	0	2	2

Coming up

2phase 3 studies under way

3studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Apr 2027A Study of COVID-19 Vaccine(s) in Children and Adults · Phase 3 · BioNTech SE
Oct 2027A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease · Phase 3 · Pfizer
Aug 2027A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age · BioNTech SE

Who these studies take

Of the 3 Nidovirales Infections studies recruiting now, 2 (67%) set no upper age limit and 1 (33%) stop at 75 or younger. 2 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (67%) take healthy volunteers.

Recruiting studies that take each age, of 3
Age	Women	Men
10	1 (33%)	1 (33%)
18	3 (100%)	3 (100%)
30	3 (100%)	3 (100%)
40	3 (100%)	3 (100%)
50	3 (100%)	3 (100%)
65	2 (67%)	2 (67%)
75	2 (67%)	2 (67%)
85	2 (67%)	2 (67%)

Across all 21 studies, recruiting or not: 10% stop at 75 or younger and 5% at 65; 14% take children; 0% are for women only and 0% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Nidovirales Infections studies take

Of 13 phase 3 interventional studies under Nidovirales Infections, half reached primary completion within 11 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 3	11 mo5–16 · 13 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 21 of 21. search them.